Form 4: Enveric CFO Receives RSU Grant Amid Reverse Stock Split

Enveric Biosciences' CFO, Kevin Michael Coveney, was granted 40,198 restricted stock units following a 1-for-12 reverse stock split.

Summary

• Chief Financial Officer Kevin Michael Coveney acquired 40,198 restricted stock units (RSUs) of Enveric Biosciences, Inc. common stock on December 23, 2025.
• The RSUs were granted under the Company's 2020 Long-Term Incentive Plan, as amended.
• Each vested RSU entitles the reporting person to receive one share of common stock.
• Vesting schedule: one-fourth vests on the one-year anniversary of issuance (December 23, 2026), an additional one-thirty-sixth vests each month thereafter, and any remaining RSUs vest on the fourth anniversary of issuance (December 23, 2029).
• Vesting is contingent upon continued employment with the Company.
• The reported amount of securities has been adjusted to reflect a 1-for-12 reverse stock split that became effective on October 28, 2025.
• Following this transaction, the CFO beneficially owns 47,413 shares of common stock.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the reverse stock split, which often signals underlying issues or a need to maintain listing compliance. While the RSU grant is a positive for management alignment, it does not outweigh the implications of the reverse split.

Positives

• The grant of 40,198 restricted stock units to the Chief Financial Officer aligns management's interests with long-term shareholder value.
• The multi-year vesting schedule (up to four years) incentivizes the CFO's continued employment and commitment to the company's performance.

Negatives

• The 1-for-12 reverse stock split, effective October 28, 2025, often indicates a low share price and can be perceived negatively by the market, potentially signaling underlying financial challenges or a need to meet exchange listing requirements.

Risks

• The vesting of restricted stock units is conditioned upon continued employment, meaning the CFO would forfeit unvested units if employment ceases.
• Reverse stock splits, while sometimes necessary, carry the risk of further stock price decline and may not address the underlying issues that led to the low share price.

Future Outlook

The multi-year vesting schedule for the restricted stock units indicates a long-term commitment from the Chief Financial Officer, aligning their incentives with the company's future performance over the next four years, contingent on continued employment.

Management Comments

• The reporting person will be entitled to receive one share of common stock for each vested restricted stock unit.
• Vesting is conditioned upon continued employment by the Company.

Industry Context

Reverse stock splits are often observed in the biotechnology sector, particularly among smaller-cap companies like Enveric Biosciences, when share prices fall below exchange minimums, necessitating a consolidation of shares to maintain listing compliance. Such actions, while addressing compliance, do not inherently improve underlying business fundamentals.

Corporate Governance

Related Party Transactions

• Grant of 40,198 restricted stock units to Kevin Michael Coveney, the Chief Financial Officer, as part of his compensation package.

Stakeholder Impact

• Shareholders: Experience a reduction in the number of shares owned but a proportional increase in share price due to the reverse stock split. Potential dilution from future RSU vesting.
• Employees (CFO): Benefits from long-term equity compensation, contingent on continued employment.

Next Steps

• Continued employment of the CFO to ensure vesting of restricted stock units.
• Monitoring the company's stock performance post-reverse split.
• Future vesting events for the granted RSUs on December 23, 2026, and subsequent monthly and final anniversary dates.

Key Dates

Keywords

Enveric Biosciences, ENVB, Form 4, Restricted Stock Units, RSU, Insider Transaction, Reverse Stock Split, CFO Compensation, Equity Grant, Long-Term Incentive Plan